PMID: 16639169Apr 28, 2006Paper

Cognitive-behaviour therapy for schizophrenia: a review

Current Opinion in Psychiatry
Shanaya Rathod, Douglas Turkington

Abstract

Most studies demonstrating the benefits of cognitive-behaviour therapy for schizophrenia were carried out in the 1990s. The majority targeted treatment resistant positive symptoms. Recent research is now focussing on the impact of cognitive-behaviour therapy on prodromal states, acute schizophrenia, negative symptoms, loss of insight and relapse prevention. There is mounting evidence to suggest that cognitive-behaviour therapy is an effective adjunct to antipsychotic medication in the management of positive symptoms of acute schizophrenia as well as negative and residual symptoms of chronic schizophrenia. The effect size at the end of therapy is strong, with durability at short-term follow up. There is also evidence that cognitive-behaviour therapy can be combined with family therapy and assertive community treatment programs targeted to reduce relapse. Cognitive-behaviour therapy improves the prognosis of patients with schizophrenia through improved adherence and symptom management leading to reduced relapse. It may prevent transition to psychosis in high-risk prodromal states. In conclusion, recent literature provides fairly strong evidence that cognitive-behaviour therapy in addition to antipsychotic medication is effective ...Continue Reading

References

Nov 1, 1979·Psychiatry·R W HoleA T Beck
Jun 1, 1993·The American Journal of Psychiatry·X F AmadorJ M Gorman
Feb 10, 1996·BMJ : British Medical Journal·R KempA David
Sep 1, 1996·The American Journal of Psychiatry·X F AmadorJ M Gorman
Mar 21, 1998·The Journal of Clinical Psychiatry·G B CassanoL Dell'Osso
Sep 25, 1998·The British Journal of Psychiatry : the Journal of Mental Science·A HealeyA David
Apr 11, 2001·Schizophrenia Research·R A GouldD Goff
May 31, 2001·The Journal of Nervous and Mental Disease·N A Rector, A T Beck
Jun 4, 2002·The British Journal of Psychiatry : the Journal of Mental Science·Douglas TurkingtonUNKNOWN Insight into Schizophrenia Research Group
Jun 5, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Douglas Turkington, Peter J McKenna
Aug 2, 2003·Schizophrenia Research·Neil A RectorZindel V Segal
Aug 2, 2003·Schizophrenia Research·Patrick KingsepDavid Castle
Sep 2, 2003·The British Journal of Psychiatry : the Journal of Mental Science·Elizabeth WalshUNKNOWN UK700 Group
Oct 11, 2003·BMJ : British Medical Journal·Colin O'DonnellEadbhard O'Callaghan
Mar 3, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Nicholas TarrierGraham Dunn
Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Stephen AlmondTraolach Brugha
May 11, 2004·Social Psychiatry and Psychiatric Epidemiology·Elizabeth KuipersUNKNOWN Croydon Outreach and Assertive Support Team (COAST)
Jul 30, 2004·Current Pharmaceutical Design·L Marcinko, M Read
Aug 12, 2004·Psychopathology·Charles Henry, S Nassir Ghaemi
Sep 1, 2004·Journal of Psychiatric Practice·Douglas TurkingtonAaron T Beck
Oct 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Anthony P MorrisonRichard P Bentall

❮ Previous
Next ❯

Citations

Jan 24, 2008·Journal of Psychiatric Practice·Shanaya RathodDouglas Turkington
Nov 18, 2008·Journal of Psychiatric and Mental Health Nursing·C H J Williams
Jul 25, 2014·Human Psychopharmacology·Takefumi SuzukiMasaru Mimura
Aug 30, 2008·Nordic Journal of Psychiatry·J MäkinenH Koponen
Feb 20, 2016·Social Psychiatry and Psychiatric Epidemiology·Frank SirotichJanet Durbin
Jul 29, 2010·Expert Review of Neurotherapeutics·Molly K LarsonMichael T Compton
Jul 1, 2017·Frontiers in Psychiatry·Laurent Morin, Nicolas Franck

❮ Previous
Next ❯

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here